Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

T

Trevi Therapeutics

Status and phase

Completed
Phase 3
Phase 2

Conditions

Nodularis Prurigo
Prurigo Nodularis
Prurigo

Treatments

Drug: nalbuphine HCl ER

Study type

Interventional

Funder types

Industry

Identifiers

NCT02174432
2013-005628-41 (EudraCT Number)
TR03ext

Details and patient eligibility

About

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

Enrollment

36 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject completed participation in the TR03 study

Exclusion criteria

  • Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study.
  • Subject is a pregnant or lactating female

Trial design

36 participants in 1 patient group

nalbuphine HCl ER
Experimental group
Description:
nalbuphine HCl ER
Treatment:
Drug: nalbuphine HCl ER

Trial documents
2

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems